MedTrace Logo

Nalfurafine Hydrochloride for Pruritus in Patients With Primary Biliary Cholangitis

NCT02659696 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 44

Last updated 2018-04-26

No results posted yet for this study

Summary

Nalfurafine hydrochloride is a selective kappa-opioid receptor agonist developed in Japan, and in May 2015 the use of nalfurafine hydrochloride was officially approved in Japan for pruritus in patients with chronic liver diseases including PBC. In the current study, the investigators aimed to assess pruritus and overall QOL before and after administration of nalfurafine hydrochloride in patients with PBC. Furthermore, the investigators took serum sample from the enrolled patients and examine the association of pruritus with possible biomarkers.

Conditions

  • Primary Biliary Cirrhosis

Sponsors & Collaborators

  • Teikyo University

    lead OTHER

Principal Investigators

  • Atsushi Tanaka, MD, PhD · Teikyo University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-12-31
Completion
2018-03-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02659696 on ClinicalTrials.gov